EGFR and head and neck squamous cell carcinoma: We propose that patients with HNSCC could be selected for RIT with [177Lu]Lu-labeled anti-EGFR mAbs by positron emission tomography (PET) with the corresponding [64Cu]Cu-labeled mAbs [Eβ+max = 0.65 MeV (17.4%)] in a “PET theranostic” strategy.